Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44 33 3023 7300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees31
Next Earnings DateN/A
OptionableNot Optionable
Mereo BioPharma Group (LON:MPH) Frequently Asked Questions
What is Mereo BioPharma Group's stock symbol?
Mereo BioPharma Group trades on the London Stock Exchange (LON) under the ticker symbol "MPH."
Has Mereo BioPharma Group been receiving favorable news coverage?
News headlines about MPH stock have trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mereo BioPharma Group earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Mereo BioPharma Group.
Who are some of Mereo BioPharma Group's key competitors?
Some companies that are related to Mereo BioPharma Group include Exicure (XCUR), IMV (IMV), Bioventix (BVXP), Arix Bioscience (ARIX), CorMedix (CRMD), Senesco Technologies (ELOX), Ergomed (ERGO), Ampliphi Biosciences (APHB), BioTime (BTX), MediGene (MDG1), CorMedix (CRMD), IMV (IMV), Emerald Health Therapeutics (EMH), Verseon (VSN) and Cynata Therapeutics (CYP).
What other stocks do shareholders of Mereo BioPharma Group own?
Who are Mereo BioPharma Group's key executives?
Mereo BioPharma Group's management team includes the folowing people:
- Dr. Denise Scots-Knight, Co-Founder, Chief Exec. Officer & Exec. Director (Age 60)
- Mr. Richard Crispin Morgan Jones, CFO & Exec. Director (Age 53)
- Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 50)
- Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 49)
- Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 62)
How do I buy shares of Mereo BioPharma Group?
Shares of MPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Mereo BioPharma Group's stock price today?
One share of MPH stock can currently be purchased for approximately GBX 55.
How big of a company is Mereo BioPharma Group?
What is Mereo BioPharma Group's official website?
How can I contact Mereo BioPharma Group?
Mereo BioPharma Group's mailing address is 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom. The company can be reached via phone at 44 33 3023 7300.
MarketBeat Community Rating for Mereo BioPharma Group (LON MPH)
MarketBeat's community ratings are surveys of what our community members think about Mereo BioPharma Group and other stocks. Vote "Outperform" if you believe MPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
